[1]
|
Li, C.J., Liu, X.J., Bai, L., Yu, Q., Zhang, Q.M., Yu, P. and Yu, D.M. (2014) Efficacy and Safety of Vildagliptin, Saxagliptin or Sitagliptin as Add-On Therapy in Chinese Patients with Type 2 Diabetes Inadequately Controlled with Dual Combination of Traditional Oral Hypoglycemic Agents. Diabetology & Metabolic Syndrome, 6, 1-9. http://dx.doi.org/10.1186/1758-5996-6-69
|
[2]
|
Qaseem, A., Linda, L.H., Donna, E.S., Melissa, S. and Paul, S. (2012) Oral Pharmacologic Treatment of Type 2 Diabetes Mellitus: A Clinical Practice Guideline from the American College of Physicians. Annals of Internal Medicine, 156, 218-231. http://dx.doi.org/10.7326/0003-4819-156-3-201202070-00011
|
[3]
|
Saine, M.E., Carbonari, D.M., Newcomb, C.W., Melissa, S.N., Kevin, H., Vincent, L.R., et al. (2015) Determinants of Saxagliptin Use among Patients with Type 2 Diabetes Mellitus Treated with Oral Anti-Diabetic Drugs. BMC Pharmacology and Toxicology, 16, 1-16. http://dx.doi.org/10.1186/s40360-015-0007-z
|
[4]
|
Scheen, A.J., Charpentier, G., Ostgren, C.J., Hellqvist, A. and Gause-Nilsson, I. (2010) Efficacy and Safety of Saxagliptin in Combination with Metformin Compared with Sitagliptin in Combination with Metformin in Adult Patients with Type 2 Diabetes Mellitus. Diabetes Metabolism Research and Reviews, 26, 540-549. http://dx.doi.org/10.1002/dmrr.1114
|
[5]
|
Deacon, C.F. (2011) Dipeptidyl Peptidase-4 Inhibitors in the Treatment of Type 2 Diabetes: A Comparative Review. Diabetes, Obesity and Metabolism, 13, 7-18. http://dx.doi.org/10.1111/j.1463-1326.2010.01306.x
|
[6]
|
Michael, E.C. and Robert, F. (2012) Saxagliptin for the Treatment of Type 2 Diabetes Mellitus: Assessing Cardiovascular Data. Cardiovascular Diabetology, 11, 1-8.
|
[7]
|
Sravana Kumara, K. and Sailaja, B. (2015) Analytical Method Development and Validation for Estimation of Dipeptidyl Peptidase-4 Inhibitors: A Review. International Journal of Current Research in Chemistry and Pharmaceutical Sciences, 2, 83-98.
|
[8]
|
Kalaichelvi, R. and Jayachandran, E. (2011) Validated Spectroscopic Method for estimation of Saxagliptin in Pure and from Tablet Formulation. International Journal of Pharmacy and Pharmaceutical Sciences, 3, 179-180.
|
[9]
|
Ramalingam, K. and Jayachandran, E. (2012) Extractive Spectrophotometric Estimation of Saxagliptin in Pure and in Pharmaceutical Dosage Form. American Journal of Pharma Tech Research, 2, 429-433.
|
[10]
|
Serife, E.K.T., Mustafa, V.K. and Demet, D. (2013) An HPLC Method for the Determination of Saxagliptin in Human Plasma with Fluorescence Detection. Journal of Advances in Chemistry, 3, 810-818.
|
[11]
|
Vaishali, V. and Anand Kumara, D. (2013) Development and Validation of a Liquid Chromatographic Method for Estimation of Saxagliptin in Tablet Dosage Form. Asian Journal of Research in Chemistry, 6, 552-554.
|
[12]
|
Gao, J., Yuan, Y., Lu, Y. and Yao, M. (2012) Development of A rapid UPLC-MS/MS Method for Quantification of Saxagliptin in Rat Plasma and Application to Pharmacokinetic Study. Biomed Chromatography, 26, 1482-1487. http://dx.doi.org/10.1002/bmc.2720
|
[13]
|
Xiaohui, X., Roger, D., Huidong, G., Lisa, J., Christophera, H.S., Laura, C., et al. (2012) Liquid Chromatography and Tandem Mass Spectrometry Method for the Quantitative Determination of Saxagliptin and Its Major Pharmacologically Active 5-Monohydroxy Metabolite in Human Plasma: Method Validation and Overcoming Specific and Non-Specific Binding at Low Concentrations. Journal of Chromatography B, 889-890, 77-86. http://dx.doi.org/10.1016/j.jchromb.2012.01.033
|